Illumina Net Income From Continuing Ops Over Time
| ILMN Stock | USD 135.43 5.70 4.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Illumina Performance and Illumina Correlation. Will Life Sciences Tools & Services sector continue expanding? Could Illumina diversify its offerings? Factors like these will boost the valuation of Illumina. Market participants price Illumina higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Illumina data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.78) | Earnings Share 4.46 | Revenue Per Share | Quarterly Revenue Growth 0.004 | Return On Assets |
Illumina's market price often diverges from its book value, the accounting figure shown on Illumina's balance sheet. Smart investors calculate Illumina's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Illumina's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Illumina and related stocks such as Quest Diagnostics, Waters, and Medpace Holdings Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DGX | 767.5 M | 507.2 M | 666.5 M | 848 M | 587 M | 753 M | 696 M | 789 M | 744 M | 886 M | 1.5 B | 2.1 B | 1 B | 819 M | 921 M | 1.1 B | 985.7 M |
| WAT | 323.3 M | 433 M | 461.4 M | 431.6 M | 431.6 M | 469.1 M | 521.5 M | 20.3 M | 593.8 M | 592.2 M | 521.6 M | 692.8 M | 707.8 M | 653.1 M | 637.8 M | 733.5 M | 545.7 M |
| MEDP | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (8.7 M) | 13.4 M | 39.1 M | 73.2 M | 100.4 M | 145.4 M | 181.8 M | 245.4 M | 273.2 M | 404.4 M | 465 M | 488.3 M |
| ZBH | 717.4 M | 760 M | 752.9 M | 759.2 M | 719 M | 146.2 M | 304.6 M | 1.8 B | (379.3 M) | 1.1 B | (137.4 M) | 402.1 M | 291.2 M | 475.2 M | 905.2 M | 814.7 M | 462.9 M |
| HOLX | (2.2 B) | (73.6 M) | (1.2 B) | 78.9 M | 222.8 M | 499.8 M | 755.5 M | (111.3 M) | (203.6 M) | 1.1 B | 1.9 B | 1.3 B | 456 M | 789.5 M | 565.7 M | 650.6 M | 683.1 M |
| THC | 1.1 B | 100 M | 209 M | (93 M) | 98 M | 76 M | 181 M | (320 M) | 463 M | 143 M | 768 M | 1.5 B | 1000 M | 1.1 B | 4.1 B | 4.7 B | 4.9 B |
| ICLR | 102.8 M | 102.8 M | 102.8 M | 102.8 M | 172.5 M | 239.5 M | 262.2 M | 281.5 M | 322.7 M | 375.9 M | 333 M | 153.2 M | 505.3 M | 612.3 M | 791.5 M | 910.2 M | 955.7 M |
| WST | 60.9 M | 69.2 M | 75.9 M | 106.9 M | 127.1 M | 95.6 M | 135.4 M | 141.5 M | 199.3 M | 232.8 M | 328.8 M | 641.7 M | 565.2 M | 593.4 M | 492.7 M | 566.6 M | 283.5 M |
| GMAB | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 1.2 B | 1.1 B | 1.5 B | 2.2 B | 4.8 B | 3 B | 5.5 B | 4.4 B | 7.8 B | 9 B | 9.5 B |
| LH | 555.6 M | 533.1 M | 584.8 M | 575.4 M | 512.6 M | 438 M | 733.2 M | 1.3 B | 883.9 M | 824.9 M | (900 K) | 2.4 B | 1.3 B | 861.4 M | 747.1 M | 859.2 M | 876.9 M |
Illumina and related stocks such as Quest Diagnostics, Waters, and Medpace Holdings Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Illumina | ILMN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 5200 Illumina Way, |
| Exchange | NASDAQ Exchange |
USD 135.43
Check out Illumina Performance and Illumina Correlation. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Illumina technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.